This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gerald L. Klerman, MD
Department of Psychiatry Cornell University Medical College New York, NY

James C. Ballenger, MD
Department of Psychiatry and Behavioral Sciences Medical University of South Carolina 171 Asley Ave Charleston, SC 29425

Graham D. Burrows, MD
Department of Psychiatry University of Melbourne Melbourne, Australia

Robert L. DuPont, MD
DuPont Associates, P.A.

Rockville, MD; Russell Noyes, Jr, MD
Department of Psychiatry 500 Newton Rd University of Iowa College of Medicine Iowa City, IA 52242

John C. Pecknold, MD
Department of Psychiatry Douglas Hospital 6875 Boulevard LaSalle Westmount, Quebec Canada H4H 1R3

Arthur Rifkin, MD
Department of Psychiatry The Mount Sinai School of Medicine Elmhurst, NY

Robert T. Rubin, MD, PhD
Division of Biological Psychiatry Harbor/UCLA Medical Center Torrance, CA

Richard P. Swinson, MD
Department of Psychiatry Toronto General Hospital Toronto, Ontario Canada

Arch Gen Psychiatry. 1989;46(7):670-672.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

Professor Marks and a number of distinguished psychiatrists and psychologists from several countries have written to criticize the set of our articles reporting on the first phase of the Cross-National Collaborative Panic Study, which appeared in the May 1988 issue of the ARCHIVES. Their letter raises a number of questions specific to the study's findings and comments on larger issues in the treatment of panic disorder and agoraphobia.

Establishing the Short-term Efficacy of Alprazolam for Panic Disorder and Agoraphobia.—

The main criticism of Professor Marks and associates' is that "this claim of 'efficacy' is misleading given the arguable interpretation of the data presented." To respond to this criticism, it is important to specify the criteria of efficacy being employed. Nowhere in the letter from Professor Marks et al do they state explicitly their criteria for efficacy.

In the Cross-National Collaborative Panic Study, First Phase, the criteria of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?